Healthcare providers using RXNT solutions will have instant access to state prescription drug monitoring program information at the point-of-care.
ANNAPOLIS, MD. (PRWEB) APRIL 6, 2020 – RXNT, a leader in healthcare technology solutions, is announcing a new feature that gives physicians direct access to state Prescription Drug Monitoring Programs (PDMPs) with Appriss Health‘s technology. Healthcare providers using RXNT’s Electronic Health Records and Electronic Prescribing solutions will be better equipped to identify and prevent substance abuse.
A PDMP is an electronic database for tracking controlled substance prescriptions in the United States. The program provides prescribers with timely and accurate information about patient behaviors and protects those at the highest risk. As of April 10, 2020, states that do not have an integration with Appriss include Illinois, Maryland, Nebraska, New York, and Wisconsin.
Appriss Health gives practitioners the ability to better monitor and manage controlled substance prescriptions 24/7 from anywhere. According to the U.S Centers for Disease Control and Prevention, nearly 70,000 Americans died from a drug overdose in 2019 alone. In the 10-year period from 1999-2019, over 770,000 have died due to substance abuse disorders.
“Our technology solutions are already one of the most user- and budget-friendly systems in the ambulatory care marketplace today. We’re excited to be able to combine Appriss’ leading-edge data analytics with our proven EHR and eRx solutions. We’re giving physicians a more powerful tool to safely prescribe controlled substances and help reduce the incidences of substance abuse,” said Randy Boldyga, RXNT President and CEO.
Since 1999, RXNT has provided award-winning, certified eRx, EHR, Practice Management, Medical Billing, and Full-Suite software to physician practices, healthcare providers, and billing companies. The company’s cost-effective, fully-integrated and cloud-based systems are designed to provide robust functionality while being easy to implement and use. For additional information, please visit www.rxnt.com.
For more information, please contact:
Executive Vice President, Business Development